Insider buying last 90 days
No open-market insider purchases were filed for KOD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every KOD insider filing, plotted on the chart in Gekko.Open KOD in Gekko
NASDAQ: KOD
Kodiak Sciences (KOD) Stock Analysis & Forecast
Sep 28 close
$89.92+57.57 (+178.0%)
Gekko Brief
AI summaryKodiak Sciences surged this week after its lead candidates, Zenkuda and tabirafusp-ted, met their primary endpoints in the Phase 3 DAYBREAK trial for wet age-related macular degeneration. Coverage frames the results as a potential rival to Regeneron's Eylea in a retinal drug market that could exceed $32 billion by the end of the decade, and the company has said it plans to file for regulatory approval of Zenkuda. Shares were described as up over 162% by midday Monday and hit a new 52-week high during the move, with analyst commentary weighing in on the story.
The stock closed at $89.92, up 178% on the day, and sits well above both its 50-day average of $39.40 and its 200-day average of $34.21, with the 50-day above the 200-day. The GekkoIndex reads 39.4, placing it in the Distribution zone, down 35.5 over the past five sessions. Price stands 102.8% above Gekko Fair Value of $44.33.
The next earnings date is 12 November 2026, 44 days out and beyond a typical 20-trading-day hold; the prior report on 12 August showed an EPS miss with a -5.1% reaction, against 3 beats in 8 quarters. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged +9.1% over 5 years, rising in 3 of them. Consensus among 7 firms stands at 6 buy, 1 hold, with a $64.00 target implying -28.8% versus current price.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Kodiak Sciences price vs fair value
Close $89.92200-day averageGekko Fair Value $44.33
Kodiak Sciences quick facts
- Market cap
- $5.63B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.41
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.18
- Volume
- 38.43M avg 2.75M
- 1-year return
- +473.5%
- Typical daily move
- ±7%
- Typical 20-day move
- ±18.9%
- 50-day average
- $39.40
- 200-day average
- $34.21
- Next earnings
- Nov 12
- Shares outstanding
- 62.85M
Kodiak Sciences swing-trade checklist
Kodiak Sciences scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $89.92 is above the 50-day ($39.40) and 200-day ($34.21) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
39.4, Distribution
Reading 39.4 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
102.8% above
Price is 102.8% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 44 days
Next report Nov 12, 2026, 44 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+9.1% on average
From this point in the calendar, the next 20 trading days averaged +9.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Kodiak Sciences stock chart and price history
Kodiak Sciences closed at $89.92 on Sep 28, 2026, +473.5% over the past year, inside a 52-week range of $10.94 to $95.77.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +129.9%
- 3 months
- +138.3%
- 6 months
- +143.0%
- 1 year
- +473.5%
The full KOD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KOD in Gekko
Follow Kodiak Sciences through every session
Put KOD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track KOD in GekkoFree for 7 days. No credit card required.
About Kodiak Sciences
Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for diseases of the retina. Its lead program, KSI-301, is an antibody biopolymer designed to inhibit anti-VEGF activity and is being studied in Phase IIb/III trials for conditions including wet age-related macular degeneration, diabetic macular edema, macular edema linked to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Beyond its lead candidate, Kodiak Sciences maintains an earlier-stage pipeline aimed at other retinal disorders. This includes KSI-501, a bispecific conjugate intended for retinal conditions marked by inflammation, and KSI-601, a triplet inhibitor being explored as a potential approach to dry age-related macular degeneration. These programs remain in preclinical stages of development.
The company traces its origins to 2009, when it was founded as Oligasis, LLC, later adopting the Kodiak Sciences name in September 2015. It is headquartered in Palo Alto, California. Shares of Kodiak Sciences trade on the NASDAQ under the ticker KOD.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- kodiak.com
Kodiak Sciences GekkoIndex: the smart money zone
Kodiak Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 39.4, in the Distribution zone, down 35.5 points over five sessions.
39.4Distribution
Down 35.5 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 43 | +0.5% | +5.5% | ||
| Accumulation | 191 | +2.0% | +5.2% | ||
| Neutral | 364 | +3.2% | +11.6% | ||
| Distribution (current zone) | 65 | +6.1% | +32.8% | ||
| Selling | 9 | Too few readings yet | |||
Average KOD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the KOD price, zone by zone.Track KOD in Gekko
Is Kodiak Sciences stock overvalued? Gekko Fair Value
Kodiak Sciences trades 102.8% above Gekko Fair Value of $44.33, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Kodiak Sciences shares are worth, recalculated every trading day.
$44.33
Gekko Fair Value, Sep 26, 2026
102.8% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open KOD in Gekko
Kodiak Sciences insider and Congress trading
No open-market insider purchases were filed for Kodiak Sciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in KOD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for KOD, plotted on the chart in Gekko.Open KOD in Gekko
Buybacks
Kodiak Sciences has been buying back its own shares.
- Bought back, year ended Dec 31, 2020
- $487K
- As a share of market cap
- 0.01%
From company filings.
Kodiak Sciences earnings: next date and track record
Kodiak Sciences reports on Nov 12, 2026 (44 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 12, 2026
44 days away
- EPS estimate
- −$0.99
3 of 8reports beat the EPS estimate
±10.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | −$1.05 est −$0.96 | — | −5.1% |
| May 7, 2026 | −$1.04 est −$0.70 | — | −10.6% |
| Mar 31, 2026 | −$1.04 est −$1.01 | — | +27.2% |
| Nov 13, 2025 | −$1.16 est −$1.07 | — | −3.7% |
| Aug 13, 2025 | −$1.03 est −$1.04 | — | +17.8% |
| May 14, 2025 | −$1.09 est −$0.87 | — | −17.4% |
| Mar 27, 2025 | −$0.84 est −$0.86 | — | −3.3% |
| Nov 14, 2024 | −$0.84 est −$0.90 | — | +0.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Kodiak Sciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Kodiak Sciences is $64.00, −28.8% from the last close, from 7 firms rating the stock in the last 90 days.
$64.00consensus 12-month target, −28.8% from the last close
Now $89.92Avg $64.00
Low $69High $145
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | LifeSci Capital | $145 | +61.3% |
| Sep 28 | Evercore ISI | — | — |
| Sep 28 | H.C. Wainwright | $96 | +6.8% |
| Sep 28 | Jefferies | $112 | +24.6% |
| Sep 24 | Goldman Sachs | — | — |
+32.8%average 20-day move after past Distribution readings
+9.1%average move over the next 20 trading days in the last 5 years
±7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Kodiak Sciences seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Kodiak Sciences averaged +9.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.8% | 2 of 5 |
| Next 10 trading days | −4.4% | 2 of 5 |
| Next 15 trading days | +9.4% | 3 of 5 |
| Next 20 trading days | +9.1% | 3 of 5 |
| Next 30 trading days | +21.2% | 3 of 5 |
For scale, KOD’s typical 20-trading-day move in either direction is about 18.9%.
Kodiak Sciences market cap and key statistics
Kodiak Sciences’s market cap is $5.63B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $5.63B
- EPS, TTM
- −$4.41
- Gekko Fair Value
- $44.33
Trading
- Volume
- 38.43M
- Avg volume, 20 days
- 2.75M
- 52-week high
- $95.77
- 52-week low
- $10.94
- Shares outstanding
- 62.85M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -368.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.18
- Typical daily move
- ±7%
- Typical 20-day move
- ±18.9%
Kodiak Sciences stock news this week
Coverage of Kodiak Sciences this week reads neutral: 1 positive, 6 neutral and 2 negative headlines.
- Why Kodiak Sciences Skyrocketed TodayThe Motley Fool, Sep 28
- Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results TranscriptSeeking Alpha, Sep 28
- Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trialProactive Investors, Sep 28
- Kodiak Sciences (KOD) Soars on Positive Phase 3 DAYBREAK Study ResultsGuruFocus, Sep 28
- Kodiak Sciences Says Eye Drug on Par with Regeneron's MedicineBenzinga, Sep 28
- Kodiak Sciences (NASDAQ:KOD) Hits New 52-Week High – Still a Buy?Defense World, Sep 28
Kodiak Sciences peers
Kodiak Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Kodiak Sciences stock FAQ
What is Kodiak Sciences’s market cap?
Kodiak Sciences’s market cap is $5.63B at the Sep 28, 2026 close of $89.92, with 62.85M shares outstanding.
What is the Kodiak Sciences stock forecast?
The consensus analyst 12-month price target for Kodiak Sciences is $64.00, −28.8% from the last close. Of the 7 firms that rated the stock in the last 90 days, 6 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Kodiak Sciences stock overvalued or undervalued?
On Gekko’s estimate Kodiak Sciences is overvalued: the Sep 28, 2026 close of $89.92 is 102.8% above Gekko Fair Value of $44.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Kodiak Sciences report earnings next?
Kodiak Sciences is expected to report on Nov 12, 2026 (44 days away). Analysts expect earnings of −$0.99 per share. Kodiak Sciences beat the earnings estimate in 3 of its last 8 reports, moving 10.7% on average across the report.
What is Kodiak Sciences’s 52-week high and low?
Kodiak Sciences’s 52-week high is $95.77 and its 52-week low is $10.94; it closed at $89.92 on Sep 28, 2026, +473.5% over the past year.
Is Kodiak Sciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Kodiak Sciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.